HSV-1 is an enveloped virus responsible for a range of diseases, from oral cold sores to potentially life-threatening encephalitis, affecting millions globally. Central to the virus’s ability to infect host cells is gB, a highly conserved viral fusion protein that orchestrates the merger of the viral envelope with host cell membranes, a prerequisite for viral entry. Despite its critical role, the prefusion conformation of gB has long evaded structural characterization, limiting scientists’ capacity to fully understand its function and immune interaction dynamics.

In this seminal investigation, the research team employed advanced cryo-electron microscopy (cryo-EM) techniques to capture and reconstruct the elusive prefusion state of HSV-1 gB at near-atomic resolution. This approach enabled them to visualize the spatial arrangement of gB’s domains sharply before the protein undergoes the dramatic conformational changes necessary for membrane fusion. Previous studies had predominantly characterized postfusion structures, which represent the protein after its functional role in membrane merger, thus missing the critical initial conformational landscape.

Detailed structural analysis revealed that gB adopts a highly metastable configuration in its prefusion form, stabilized by a complex network of intramolecular interactions. Notably, the fusion loops, known for inserting into host membranes during the fusion process, are sequestered in a way that prevents premature exposure, underscoring a finely tuned mechanism of activation. This conformation likely represents a vulnerable window during which neutralizing antibodies can bind and block the fusion event, a potential Achilles’ heel for the virus.

Accompanying their structural insights, the researchers also explored how HSV-1 gB subverts the host immune response. Glycoprotein B is known to be a major target for neutralizing antibodies, yet HSV-1 deftly evades neutralization, allowing persistent infections and periodic reactivation. The study uncovered that gB’s prefusion form exhibits glycan shields and conformational masking that obscure critical epitopes from immune surveillance. This strategic cloaking likely limits the efficacy of antibody binding during natural infection and highlights the challenges in eliciting protective immunity via traditional vaccine approaches.

In addition to structural characterization, the study dissected the binding properties of several potent neutralizing antibodies isolated from infected individuals. These antibodies were found to preferentially recognize and stabilize the prefusion conformation of gB, effectively locking it in a non-functional state and preventing membrane fusion. Such detailed understanding of antibody binding modes provides valuable clues for the design of immunogens capable of eliciting similarly protective responses.

Crucially, the findings have broad implications for antiviral drug development. By defining the molecular landscape of prefusion gB, the team has identified potential small-molecule binding pockets and allosteric sites that could be exploited to design fusion inhibitors. These novel antiviral agents would act by stabilizing gB in its prefusion state or by disrupting the finely balanced conformational shifts necessary for fusion, cutting off the virus at its point of entry.

From a vaccine perspective, the study lays the foundation for next-generation HSV-1 vaccines that focus on presenting the prefusion form of gB as an immunogen. Traditional HSV vaccines have struggled partly due to the dynamic nature of gB and the predominance of postfusion epitopes, which are less effective in eliciting neutralizing antibodies. Stabilizing and displaying the prefusion gB trimer could focus immune responses on functionally relevant and vulnerable sites, enhancing vaccine efficacy and durability.

Moreover, this research sheds light on the evolutionary arms race between HSV-1 and the human immune system. The elegant structural mechanisms of immune evasion documented here reflect sophisticated viral adaptation, highlighting the challenges of mounting an effective immune defense against herpesviruses. Understanding these sophisticated escape strategies also informs broader virology, as similar principles may apply to other class III fusion proteins found across diverse viral families.

The methodology used in this study is a striking example of how integrated structural biology techniques, including cryo-EM, X-ray crystallography, and computational modeling, can be leveraged to tackle previously intractable viral proteins. By synergistically combining these approaches, the authors provided not only static structural data but also dynamic insights into the conformational flexibility and activation pathways of gB, enriching the functional narrative.

Equally important, the study establishes a framework to investigate glycoprotein B homologs in related herpesviruses, such as HSV-2, varicella-zoster virus, and cytomegalovirus. Given the conserved nature of this fusion machinery, the insights gained here could accelerate cross-species antiviral strategies and foster a unified approach to combat herpesvirus infections more broadly.

The intricate dance between viral glycoproteins and host cell membranes is fundamental to viral infectivity, and this study advances our grasp on one of nature’s most complex fusion machineries. By elucidating the prefusion structure and immune evasion tactics of HSV-1 gB, this work marks a transformative leap toward therapeutic innovations that could significantly reduce the global burden of herpes simplex virus infections.

In conclusion, this landmark investigation by Roark, Schaub, Shi, and colleagues propels our understanding of HSV-1 biology into an unprecedented molecular realm. By revealing the architecture of gB before membrane fusion, decoding the immune evasion landscape, and mapping neutralization vulnerabilities, they unlock a new frontier in herpesvirus research. The translational potential of these findings for antiviral drugs and vaccines promises to energize the field and offers hope for more effective interventions against this pervasive pathogen.

Subject of Research: Structural characterization, immune evasion, and neutralization mechanisms of herpes simplex virus 1 glycoprotein B (HSV-1 gB).

Article Title: Prefusion structure, evasion and neutralization of HSV-1 glycoprotein B.

Article References:
Roark, R.S., Schaub, A.J., Shi, W. et al. Prefusion structure, evasion and neutralization of HSV-1 glycoprotein B. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02153-x

Image Credits: AI Generated

TBEV is a member of the flavivirus genus, a category that includes other prominent viruses such as dengue, yellow fever, Zika, and Japanese encephalitis viruses. These mosquito- and tick-borne pathogens are notorious for causing widespread morbidity and mortality globally. Despite extensive research, the precise host-cell proteins facilitating the entry of flaviviruses into human cells had remained unidentified until now. This study definitively demonstrates that TBEV requires interaction with a specific receptor on human cells to initiate infection, a discovery that could revolutionize efforts to combat flavivirus-related diseases.

Tick-borne encephalitis virus is predominantly transmitted via ticks, which bite humans and transfer the virus, leading to infections that can invade the central nervous system—including the brain and spinal cord—resulting in potentially fatal neurological symptoms. The incidence of TBEV infections, currently exceeding 10,000 clinical cases annually, is anticipated to rise as climate changes and expanding tick habitats enable the vector to colonize new geographic areas, spreading the disease further throughout Northern, Central, and Eastern Europe as well as Central and East Asia.

In their search for the viral receptor, the scientists utilized an expansive screening approach involving a human cell line engineered to contain thousands of genetic variants, each lacking a different gene. This loss-of-function library was exposed to TBEV under controlled experimental conditions, with surviving cells suspected of missing genes essential for viral infection. From this competitive selection, the gene encoding the receptor protein LRP8 distinctly emerged as a critical factor required for TBEV entry into human cells.

LRP8, or low-density lipoprotein receptor-related protein 8, is localized on the surface of various human cells, with particularly high expression in the brain and at the blood-brain barrier. This receptor is classically known for its roles in neurological development and neuronal signaling pathways. The study revealed that TBEV directly engages LRP8 via its envelope protein E, a glycoprotein instrumental in viral attachment, immune evasion, and propagation within the host. This interaction underpins TBEV’s ability to specifically target and infect neuronal cells, key mediators of neuropathology in TBEV infections.

Further experimental validation by researchers at USAMRIID demonstrated the in vivo relevance of LRP8 by deploying a “decoy receptor” strategy. This therapeutic approach involved administering soluble forms of the LRP8 receptor that bind TBEV in circulation, thereby preventing the virus from engaging cell surface LRP8 and blocking infection. Remarkably, the vast majority of mice treated with the decoy receptor remained free of clinical signs after exposure to a highly virulent TBEV strain, whereas untreated controls rapidly developed severe disease and succumbed. These findings underscore LRP8’s indispensable role in facilitating TBEV neuroinvasion.

Despite these promising results, the scientists emphasize that further research is essential to delineate the precise molecular mechanisms by which LRP8 mediates viral entry and subsequent neurological damage. They are particularly interested in uncovering whether TBEV exploits similar receptor pathways within ticks, which serve as natural reservoirs and vectors, completing the virus’s life cycle. Such insights could be critical for developing integrated strategies to prevent virus transmission.

Given the limited availability of TBEV vaccines, which are largely inaccessible in low- and middle-income regions within endemic zones, and the current absence of targeted antiviral therapies, this receptor discovery carries substantial clinical implications. It opens prospects for novel preventive and therapeutic interventions aimed at disrupting virus-receptor interactions, potentially mitigating the burden of tick-borne encephalitis and related flavivirus infections worldwide.

This landmark study was orchestrated by a coalition of leading scientists in virology, immunology, and infectious diseases. Among the principal investigators were Kartik Chandran, Ph.D., Eva Mittler, Ph.D., Andrew Herbert, Ph.D., and Sara Gredmark-Russ, M.D., Ph.D., whose combined expertise facilitated the comprehensive exploration of TBEV’s host-pathogen interactions. The collaborative nature of this research, spanning several continents and institutions, exemplifies the global effort necessary to confront emerging infectious diseases effectively.

The study also benefits from state-of-the-art methodologies, including genomic knockout libraries, protein-receptor binding assays, and in vivo animal models, underscoring the importance of multidisciplinary approaches in modern infectious disease research. Mapping the virus-host interface at the molecular level facilitates rapid translation of fundamental findings into applied clinical strategies.

By illuminating the critical role of LRP8 as a gateway for TBEV infection, this research signifies a paradigm shift in flavivirus biology, challenging earlier assumptions that cellular entry mechanisms were unknown. The elucidation of this receptor not only enhances our understanding of TBEV pathogenesis but also serves as a template for investigating receptor usage by other flaviviruses, which continue to impose significant global health challenges through epidemics and endemic disease burdens.

In summary, the identification of LRP8 as the receptor essential for TBEV infection constitutes a major advance in virus-host biology, with profound implications for developing antiviral drugs, designing vaccines, and improving public health responses to tick-borne encephalitis. Amidst a landscape of climate change and expanding vector habitats, such scientific breakthroughs are urgently needed to anticipate and contain emerging viral threats to human populations.

Subject of Research: Cells
Article Title: “LRP8 is a receptor for tick-borne encephalitis virus.”
News Publication Date: 24-Sep-2025
Image Credits: Albert Einstein College of Medicine
Keywords: Cell biology, Virology, Tick-borne encephalitis virus, Flavivirus, LRP8 receptor, Neurological disease, Virus-host interactions, Antiviral therapy, Viral entry mechanisms